Identification of the timing of neuronal hypoexcitability within ALS patient disease progression, the exact mechanisms by which mutant TDP-43 lowers synaptic GluR1, and modulation of synaptic GluR1 levels, may provide novel therapeutic targets for the treatment of this devastating neurodegenerative disease. This evidence concerns the gene GRIA1 and neurodegenerative disease.